Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01067 ...
Drug Name Glipizide
Molecular Weight 445.535
Molecular Formula C21H27N5O4S
CAS Number 29094-61-9
SMILES CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
External Links
DRUGBANK DB01067
T3DB T3D2483
PubChem Compound 3478
PDR 1635
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 1.91 - 1.91 - HANSCH,C ET AL. (1995)
Melting Point 201.5 ℃ 200-203 ℃ U.S. Patent 3,669,966.
Water Solubility 37.2 mg/L 37.2 mg/L DRUGBANK
pKa 5.9 - 5.9 - PANTEN,U ET AL. (1989)

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 100.0 % ~100 % PO, oral; DRUGBANK
Bioavailability 100.0 % 100 % Oral single dose; diabetes; DRUGBANK
Bioavailability 95.0 % 95.0 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 465.0 ng/ml 465±139 ng/ml PO, oral; immediate release formulation; young; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 9.0 h 6-12 h PO, oral; DRUGBANK
T Max 2.1 h 2.1±0.9 h PO, oral; immediate release formulation; young; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 3.0 L/h ~3 L/h Average clearance; intravenous injection, IV; Single dose; diabetes; patients; DRUGBANK
Clearance 0.0312 L/h/kg 0.52±0.18 ml/min/kg apparent clearance; Elderly → ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Clearance 0.0336 L/h/kg 0.56 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 10.0 L 10.0 L Average volume of distribution; diabetes; patients; DRUGBANK
Volume of Distribution 0.17 L/kg 0.17±0.02 L/kg Apparent volume of distribution; Elderly → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.16 L/kg 0.16 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 3.5 h 2-5 h elimination half-life; Single dose; type 2 diabetes; DRUGBANK
Half-life 3.5 h 2-5 h elimination half-life; Multiple dose; type 2 diabetes; DRUGBANK
Half-life 3.4 h 3.4±0.7 h RD, renal impairment, Renal disease，including uremia → ;Age → ; The Pharmacological Basis of Therapeutics
Half-life 3.3 h 3.3 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 4000.0 mg/kg >4000 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 1200.0 mg/kg 1200.0 mg/kg Intraperitoneal, IP; Rattus, Rat; DRUGBANK
Toxicity TDLo 0.38 mg/kg 379.0 ug/kg PO, oral; Children; DRUGBANK
Eliminate Route 10.0 % 10 % Urinary excretion; Faeces excretion; Unchanged drug; DRUGBANK
Eliminate Route 5.0 % <5 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 98.5 % 98-99 % DRUGBANK
Protein Binding 98.4 % 98.4 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for adults 20.0 mg/day 20 mg/day Tablet,PO，oral Glucotrol glipizide PDR
Max dose for adults 40.0 mg/day 40 mg/day Tablet,PO，oral Glucotrol glipizide PDR
Max dose for geriatric 20.0 mg/day 20 mg/day Tablet,PO，oral Glucotrol glipizide PDR
Max dose for geriatric 40.0 mg/day 40 mg/day Tablet,PO，oral Glucotrol glipizide PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1